In a recent legal development, Hindustan Unilever (NS: HLL) faced a setback regarding a tax dispute involving a significant ...

The global gynecology drugs market was valued at approximately USD 66.44 billion in 2023 and is projected to experience a healthy compound annual growth rate (CAGR) of 4.8% from 2024 to 2032, reaching ...

GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced that the Arexvy vaccine (MAL24086007ARZ) has been approved in Malaysia for respiratory syncytial virus (RSV). RSV is a common respiratory ...

Arexvy has been approved in Malaysia for RSV (respiratory syncytial virus), for older adults aged 60 and above. The vaccine ...

Cancer Vaccines Market revenue is expected to hold around USD 24.22 billion by 2033 from USD 9 million in 2023 with a ...

(Alliance News) - GSK PLC on Tuesday announced a new positive opinion from the EU's European Medicine Agency's Committee for Medicinal Products for Human Use. The London-based pharmaceutical company ...

Falak is a newly built Grade A office building located in the heart of Dubai Internet City (DIC), offering over 90,000 square ...

DoctorsOfJoy aims to highlight how dentists empower individuals to fully enjoy life's moments by addressing oral health ...

NewZNew - Sensodyne Celebrates World Dentist Day with #DoctorsOfJoy Campaign: Sensodyne, a leading oral care brand from ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on GlaxoSmithKline (GB:GSK – Research Report), Sonova Holding AG (CH:SOON – Research Report) and Corbus Pharmaceuticals ...

The 13 drugs most likely to be chosen for CMS negotiations, according to the study: Ozempic, Rybelsus and Wegovy (semaglutide): Novo Nordisk's treatment for Type 2 diabetes and weight management.

Parkinson’s is the fastest growing neurological condition in the world and affects around 153,000 people in the UK.